Clinical trial
GALLANT 4 Tesaglitazar vs. Glibenclamide
NCT00255541 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00255541 |
|---|---|
| Title | GALLANT 4 Tesaglitazar vs. Glibenclamide |
| Official title | A 52-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes |
| Intervention type | Drug |
| Interventions | Tesaglitazar, Glibenclamide |
| Enrollment | 580 |
| Start date | Sep 1, 2004 |
| Completion | Dec 1, 2006 |
| First posted | Nov 21, 2005 |
| Last update posted | Mar 17, 2008 |
| Countries | Belgium, Hong Kong, Hungary, Italy, Malaysia, Mexico, Norway, Philippines, Poland, Slovakia, South Africa, Taiwan and 1 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: